Teva Pharmaceutical Industries (TEVA) Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Assets data on file, last reported at $40.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 4.23% year-over-year to $40.0 billion; the trailing twelve-month figure through Mar 2026 stood at $40.0 billion (up 4.23% YoY), and the FY2025 full-year result was $40.7 billion, up 3.62% from the prior year.
• Assets for Q1 2026 stood at $40.0 billion, down from $40.7 billion in the prior quarter.
• Across five years, Assets topped out at $47.1 billion in Q1 2022 and bottomed at $38.4 billion in Q1 2025.
• A 5-year average of $42.2 billion and a median of $42.1 billion in 2023 frame the typical range for Assets.
• Across the five-year window, Assets fell 10.19% in 2025 and climbed 4.23% in 2026, its largest moves.
• Tracing TEVA's Assets over 5 years: stood at $44.0 billion in 2022, then slipped by 1.21% to $43.5 billion in 2023, then slipped by 9.55% to $39.3 billion in 2024, then advanced by 3.62% to $40.7 billion in 2025, then dropped by 1.74% to $40.0 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $40.0 billion, $40.7 billion, and $39.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison